12:00 AM
Jan 21, 2013
 |  BC Week In Review  |  Company News  |  Other News

Biogen Idec, Classen Immunotherapies Inc., GlaxoSmithKline, Merck, Novartis pharmaceuticals news

The U.S. Supreme Court denied a petition from GlaxoSmithKline to review a decision from the U.S. Court of Appeals ruling that two of three disputed patents from Classen are patent-eligible under Section 101 of the Patent Act. In 2011, the CAFC reconsidered Classen Immunotherapies Inc. v....

Read the full 208 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >